128 related articles for article (PubMed ID: 17577047)
21. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L
Front Immunol; 2021; 12():778459. PubMed ID: 34777395
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.
Vlasveld LT; Hekman A; Vyth-Dreese FA; Rankin EM; Scharenberg JG; Voordouw AC; Sein JJ; Dellemijn TA; Rodenhuis S; Melief CJ
Br J Cancer; 1993 Sep; 68(3):559-67. PubMed ID: 8353046
[TBL] [Abstract][Full Text] [Related]
23. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
[TBL] [Abstract][Full Text] [Related]
24. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.
Liotta F; Gacci M; Frosali F; Querci V; Vittori G; Lapini A; Santarlasci V; Serni S; Cosmi L; Maggi L; Angeli R; Mazzinghi B; Romagnani P; Maggi E; Carini M; Romagnani S; Annunziato F
BJU Int; 2011 May; 107(9):1500-6. PubMed ID: 20735382
[TBL] [Abstract][Full Text] [Related]
25. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
[TBL] [Abstract][Full Text] [Related]
26. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
Dutcher JP
Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
[No Abstract] [Full Text] [Related]
27. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
Ali SA; Rees RC; Anderson DQ; Reed MW; Goepel JR; Brown NJ
Br J Cancer; 2000 Oct; 83(8):1061-8. PubMed ID: 10993655
[TBL] [Abstract][Full Text] [Related]
28. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
29. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients.
McCarter MD; Baumgartner J; Escobar GA; Richter D; Lewis K; Robinson W; Wilson C; Palmer BE; Gonzalez R
Ann Surg Oncol; 2007 Oct; 14(10):2854-60. PubMed ID: 17593331
[TBL] [Abstract][Full Text] [Related]
31. [Influence of immunological parameters on the effectiveness of systemic and loco-regional immunotherapy in disseminated renal carcinoma].
Granov AM; Molchanov OE; Karelin MI; Shkol'nik MI; Krotova OA
Vopr Onkol; 2009; 55(5):580-5. PubMed ID: 20020653
[TBL] [Abstract][Full Text] [Related]
32. [Lymphocyte subpopulations in patients with skin basalioma of the trunk].
Röcken M; Link C; Weber T; Nerl C
Z Hautkr; 1989 Mar; 64(3):212-7. PubMed ID: 2566213
[TBL] [Abstract][Full Text] [Related]
33. Differential changes in CD4+ and CD8+ effector and regulatory T lymphocyte subsets in the testis of rats undergoing autoimmune orchitis.
Jacobo P; Guazzone VA; Jarazo-Dietrich S; Theas MS; Lustig L
J Reprod Immunol; 2009 Jul; 81(1):44-54. PubMed ID: 19520436
[TBL] [Abstract][Full Text] [Related]
34. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
35. Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.
Seung SK; Curti BD; Crittenden M; Walker E; Coffey T; Siebert JC; Miller W; Payne R; Glenn L; Bageac A; Urba WJ
Sci Transl Med; 2012 Jun; 4(137):137ra74. PubMed ID: 22674552
[TBL] [Abstract][Full Text] [Related]
36. Prolonged continuous infusion of low-dose rIL-2.
Janssen RA; Buter J; The TH; Mulder NH; de Leij L
Br J Cancer; 1994 May; 69(5):976-7. PubMed ID: 8180034
[No Abstract] [Full Text] [Related]
37. Interleukin 2 in cancer therapy.
Antony GK; Dudek AZ
Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
[TBL] [Abstract][Full Text] [Related]
38. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
[No Abstract] [Full Text] [Related]
39. Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients.
Crocenzi TS; Tretter CP; Schwaab T; Schned AR; Heaney JA; Cole BF; Fisher JL; Ernstoff MS
Clin Immunol; 2005 Oct; 117(1):6-11. PubMed ID: 16027041
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-2, interleukin-6 and T regulatory cells in peripheral blood of patients with Behçet's disease and recurrent aphthous ulcerations.
Pekiner FN; Aytugar E; Demirel GY; Borahan MO
J Oral Pathol Med; 2012 Jan; 41(1):73-9. PubMed ID: 21736625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
